A retrospective study on immune-related pneumonitis in patients with non-small-cell lung cancer undergoing treatment with PD-1/PD-L1 inhibitors

ABSTRACTBackground Lung cancer patients undergoing treatment with immune checkpoint inhibitors (ICIs) are at risk of developing immune-related (ir-)pneumonitis. Since lung cancer patients have competing reasons for respiratory symptoms, this poses a diagnostic challenge. This study aimed to explore...

Full description

Bibliographic Details
Main Authors: Dorthe Yakymenko, Kristin Skougaard
Format: Article
Language:English
Published: Taylor & Francis Group 2023-01-01
Series:European Clinical Respiratory Journal
Subjects:
Online Access:https://www.tandfonline.com/doi/10.1080/20018525.2023.2194162
_version_ 1797448952939806720
author Dorthe Yakymenko
Kristin Skougaard
author_facet Dorthe Yakymenko
Kristin Skougaard
author_sort Dorthe Yakymenko
collection DOAJ
description ABSTRACTBackground Lung cancer patients undergoing treatment with immune checkpoint inhibitors (ICIs) are at risk of developing immune-related (ir-)pneumonitis. Since lung cancer patients have competing reasons for respiratory symptoms, this poses a diagnostic challenge. This study aimed to explore diagnosis and management of ir-pneumonitis in this patient group.Materials and Methods Retrospective database retrieved analysis of patients with non-small cell lung cancer undergoing treatment with PD-1/PD-L1 inhibitors at Department of Oncology, Copenhagen University Hospital, Herlev. Patients being suspected of ir-pneumonitis during the period 01.07.2016 – 15.06-2020 were selected.Results Out of 377 eligible patients, 83 were suspected of ir-pneumonitis. A thoracic computed tomography (CT) was made in 93% of the patients, and 34% had a sputum sample made. A specialist in pulmonology was consulted in seven patient cases. Ir-pneumonitis was radiologically confirmed in 34 patients, however, in 12 patients symptoms could not be confined to ir-pneumonitis and only 22 patients were included in the analysis of the course of treatment. Solely corticosteroids were used as systemic treatment, and the median duration of treatment was 16 weeks (4-34). In seven patients pneumonitis was consistent with recall radiation pneumonitis (RRP).Conclusion Suspected ir-pneumonitis was frequent in this group of patients. The cohort was characterized by high heterogeneity and lack of unequivocal diagnostic conclusions. Treatment of ir-pneumonitis was longer than recommended and involvement of pulmonologist was very infrequent. The result of this study reflects the difficulties in a daily clinical setting to diagnose and manage patients with lung cancer presenting with pulmonary symptoms.
first_indexed 2024-03-09T14:18:01Z
format Article
id doaj.art-bf9b94b5a6dc43aaadb4e50cc909b58e
institution Directory Open Access Journal
issn 2001-8525
language English
last_indexed 2024-03-09T14:18:01Z
publishDate 2023-01-01
publisher Taylor & Francis Group
record_format Article
series European Clinical Respiratory Journal
spelling doaj.art-bf9b94b5a6dc43aaadb4e50cc909b58e2023-11-28T19:19:58ZengTaylor & Francis GroupEuropean Clinical Respiratory Journal2001-85252023-01-0110110.1080/20018525.2023.2194162A retrospective study on immune-related pneumonitis in patients with non-small-cell lung cancer undergoing treatment with PD-1/PD-L1 inhibitorsDorthe Yakymenko0Kristin Skougaard1Department of Oncology, Copenhagen University Hospital, Herlev, DenmarkCentre for Medicines Licensing & Pharmacovigilance Oncology & Hematology, Danish Medicines Agency, Copenhagen, DenmarkABSTRACTBackground Lung cancer patients undergoing treatment with immune checkpoint inhibitors (ICIs) are at risk of developing immune-related (ir-)pneumonitis. Since lung cancer patients have competing reasons for respiratory symptoms, this poses a diagnostic challenge. This study aimed to explore diagnosis and management of ir-pneumonitis in this patient group.Materials and Methods Retrospective database retrieved analysis of patients with non-small cell lung cancer undergoing treatment with PD-1/PD-L1 inhibitors at Department of Oncology, Copenhagen University Hospital, Herlev. Patients being suspected of ir-pneumonitis during the period 01.07.2016 – 15.06-2020 were selected.Results Out of 377 eligible patients, 83 were suspected of ir-pneumonitis. A thoracic computed tomography (CT) was made in 93% of the patients, and 34% had a sputum sample made. A specialist in pulmonology was consulted in seven patient cases. Ir-pneumonitis was radiologically confirmed in 34 patients, however, in 12 patients symptoms could not be confined to ir-pneumonitis and only 22 patients were included in the analysis of the course of treatment. Solely corticosteroids were used as systemic treatment, and the median duration of treatment was 16 weeks (4-34). In seven patients pneumonitis was consistent with recall radiation pneumonitis (RRP).Conclusion Suspected ir-pneumonitis was frequent in this group of patients. The cohort was characterized by high heterogeneity and lack of unequivocal diagnostic conclusions. Treatment of ir-pneumonitis was longer than recommended and involvement of pulmonologist was very infrequent. The result of this study reflects the difficulties in a daily clinical setting to diagnose and manage patients with lung cancer presenting with pulmonary symptoms.https://www.tandfonline.com/doi/10.1080/20018525.2023.2194162Lung cancerImmune Checkpoint InhibitorPneumonitis
spellingShingle Dorthe Yakymenko
Kristin Skougaard
A retrospective study on immune-related pneumonitis in patients with non-small-cell lung cancer undergoing treatment with PD-1/PD-L1 inhibitors
European Clinical Respiratory Journal
Lung cancer
Immune Checkpoint Inhibitor
Pneumonitis
title A retrospective study on immune-related pneumonitis in patients with non-small-cell lung cancer undergoing treatment with PD-1/PD-L1 inhibitors
title_full A retrospective study on immune-related pneumonitis in patients with non-small-cell lung cancer undergoing treatment with PD-1/PD-L1 inhibitors
title_fullStr A retrospective study on immune-related pneumonitis in patients with non-small-cell lung cancer undergoing treatment with PD-1/PD-L1 inhibitors
title_full_unstemmed A retrospective study on immune-related pneumonitis in patients with non-small-cell lung cancer undergoing treatment with PD-1/PD-L1 inhibitors
title_short A retrospective study on immune-related pneumonitis in patients with non-small-cell lung cancer undergoing treatment with PD-1/PD-L1 inhibitors
title_sort retrospective study on immune related pneumonitis in patients with non small cell lung cancer undergoing treatment with pd 1 pd l1 inhibitors
topic Lung cancer
Immune Checkpoint Inhibitor
Pneumonitis
url https://www.tandfonline.com/doi/10.1080/20018525.2023.2194162
work_keys_str_mv AT dortheyakymenko aretrospectivestudyonimmunerelatedpneumonitisinpatientswithnonsmallcelllungcancerundergoingtreatmentwithpd1pdl1inhibitors
AT kristinskougaard aretrospectivestudyonimmunerelatedpneumonitisinpatientswithnonsmallcelllungcancerundergoingtreatmentwithpd1pdl1inhibitors
AT dortheyakymenko retrospectivestudyonimmunerelatedpneumonitisinpatientswithnonsmallcelllungcancerundergoingtreatmentwithpd1pdl1inhibitors
AT kristinskougaard retrospectivestudyonimmunerelatedpneumonitisinpatientswithnonsmallcelllungcancerundergoingtreatmentwithpd1pdl1inhibitors